Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Some claims align with label-supported interactions (bleeding risk with concomitant anticoagulants/antiplatelets/NSAIDs) and renal impairment dosing rationale, but many interaction/PK specifics (transporter/enzymes, PPI/antacid timing, specific symptom examples, “clinicians often adjust and monitor,” and inclusion of specific interacting drugs) are not supported by the provided prescribing information excerpts.
Category Scores
Accurate Statements
Combining Savaysa (edoxaban) with other anticoagulants and antiplatelet drugs can increase bleeding risk.
Section 7.1: Co-administration of anticoagulants and antiplatelet drugs (and aspirin/platelet aggregation inhibitors) may increase risk of bleeding.
NSAIDs and some pain medicines can increase bleeding risk in some patients taking Savaysa (edoxaban).
Section 7.1: concomitant NSAIDs may increase risk of bleeding; promptly evaluate signs/symptoms of blood loss if treated concomitantly with NSAIDs.
The exact interaction risk with edoxaban depends on the specific antibiotic, antifungal, or antiviral drug.
Supported in a general sense only by Section 7.1 requiring evaluation of signs/symptoms of blood loss with concomitant interacting agents; however no specific antibiotic/antifungal/antiviral details are provided in the excerpts.
Edoxaban dosing and interaction risk can depend on kidney function.
Section 8.6 Renal Impairment: renal clearance ~50% of total clearance; reduced renal function increases blood levels and dosing is reduced (CrCL 15-50 mL/min).
If kidney function is reduced, medicines that further increase edoxaban exposure can have a bigger bleeding impact.
Section 8.6: increased edoxaban blood levels in poor renal function; risk considerations (blood levels increased). No explicit statement about “further exposure” medicines being bigger impact is included in provided excerpts.
Unsupported Statements
Savaysa (edoxaban) can interact with medicines that change blood-clotting risk.
Not explicitly supported in the provided excerpts; label excerpt specifically addresses increased bleeding risk with certain concomitant drug classes (anticoagulants/antiplatelets/thrombolytics/SSRIs-SNRIs) rather than generic “blood-clotting risk.”
Savaysa (edoxaban) can interact with medicines that affect how edoxaban is absorbed and cleared by the body.
Not supported by provided excerpts; no absorption/clearance interaction mechanisms are described in the excerpted label sections.
Strong drugs that affect edoxaban transporters or enzymes can raise or lower edoxaban levels.
No transporter/enzymes interaction content is present in the provided label excerpts.
The highest-risk combinations are usually those that also affect clotting.
Not stated in the provided excerpts.
Combining Savaysa (edoxaban) with other anticoagulants (for example, warfarin, heparin, apixaban, rivaroxaban, dabigatran) can raise bleeding risk.
Section 7.1 supports increased bleeding risk with anticoagulants generally, but the specific list of example drugs is not provided in the excerpts.
Combining Savaysa (edoxaban) with antiplatelet therapy (for example, aspirin or clopidogrel) can raise bleeding risk.
Aspirin is supported as an example in Section 7.1, but clopidogrel is not mentioned in provided excerpts.
Some NSAIDs can increase stomach or intestinal bleeding risk.
No label excerpt provided describing stomach/intestinal localization of bleeding with NSAIDs.
Clinicians often adjust therapy and monitor closely for bleeding when these higher-risk combinations are used together.
Label excerpt says to promptly evaluate signs/symptoms of blood loss when treated concomitantly; it does not state “clinicians often adjust therapy” or provide guidance framed as general practice.
Some acid-reducing therapies can change drug absorption for oral anticoagulants.
No PPI/antacid information is present in the provided excerpts.
Whether a proton-pump inhibitor (PPI) or antacid significantly affects edoxaban depends on the product and timing.
No PPI/antacid statements in provided excerpts.
Some antibiotic and antifungal medicines can strongly affect edoxaban blood levels by changing transporter or enzyme activity.
No antibiotic/antifungal/transporters/enzymes content is present in the provided excerpts.
Some antiviral medicines can strongly affect edoxaban blood levels by changing transporter or enzyme activity.
No antiviral/transporters/enzymes content is present in the provided excerpts.
Antibiotic, antifungal, and antiviral medicines are common sources of clinically important interactions with oral anticoagulants.
Not supported by provided excerpts.
Bleeding-related symptoms that can indicate a problematic interaction or excessively high anticoagulant effect include unusual bruising / nosebleeds or bleeding gums / blood in urine or dark/tarry stools / coughing or vomiting blood / severe headache, dizziness, or weakness.
No specific symptom list is provided in the provided excerpts. Section 7.1 mentions evaluating signs/symptoms of blood loss generally, and the boxed warning excerpt includes neurological impairment monitoring, but the specific symptom enumeration is not supported.
Seeking urgent care is recommended for signs of serious bleeding or neurologic symptoms.
No instructions about “seeking urgent care” are included in provided excerpts. The spinal/epidural section says urgent treatment is necessary if neurological compromise is noted, but not “urgent care” phrasing.
An updated list of all prescriptions, OTC drugs (especially NSAIDs), and supplements can help manage interaction problems day-to-day.
Not supported by provided label excerpts.
Do not start or stop interacting drugs without the prescriber.
Not supported by provided excerpts.
Savaysa should be taken exactly as directed.
No administration instruction excerpt regarding “exactly as directed” is provided.
Changing timing of Savaysa can matter for some interacting medications.
No timing-related interaction guidance is provided in the excerpts.
Contradictions
Important Omissions
Boxed Warning B detail: premature discontinuation increases risk of ischemic events; transition/coverage guidance depends on adequate alternative anticoagulation.
Importance:
Moderate
Renal dosing restriction for CrCL > 95 mL/min: Savaysa should not be used in NVAF patients with CrCL > 95 mL/min.
Importance:
Moderate
Spinal/epidural hematoma warning elements: monitor frequently for neurological impairment and urgent treatment if neurological compromise noted (neuraxial anesthesia/spinal puncture context).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Many detailed interaction claims and symptom/urgency instructions are not supported by provided label excerpts. While the general bleeding-risk and renal-impairment concepts align with the label, unsupported specifics could mislead users about the nature and immediacy of risks.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Partially Aligned
Primary Issue
Numerous interaction mechanism claims (transporters/enzymes), PPI/antacid and specific antibiotic/antifungal/antiviral details, and symptom/urgency guidance are not supported by the provided prescribing-information excerpts.
Suggested Improvement
Limit interaction statements to what is explicitly supported (e.g., increased bleeding risk with concomitant anticoagulants/antiplatelets/NSAIDs/SSRIs-SNRIs and prompt evaluation of blood loss signs), and incorporate boxed-warning-specific and renal-dosing-specific label limits (CrCL > 95 mL/min not recommended; spinal/epidural neurological monitoring/urgent treatment).